Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 12/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24358207 | 1.00 | TRPV1 (0.40) | TRPV1MAP3K12SCN9ASLC2A1SYK | |
| SCHEMBL24357959 | 0.91 | MAP3K12 (0.39) | MAP3K12SYKIDH2 | |
| SCHEMBL29601176 | 0.91 | MAP3K12 (0.39) | MAP3K12SYKIDH2 | |
| SCHEMBL30745778 | 0.86 | KDR (0.44) | MAP3K12SYKIDH2 | |
| SCHEMBL24358155 | 0.86 | KDR (0.44) | MAP3K12SYKIDH2 | |
| SCHEMBL24358235 | 0.85 | MAP3K12 (0.42) | TRPV1MAP3K12SLC2A1SYK | |
| SCHEMBL30745665 | 0.85 | MAP3K12 (0.42) | TRPV1MAP3K12SLC2A1SYK | |
| SCHEMBL29601680 | 0.85 | KDR (0.43) | MAP3K12SYKIDH2 | |
| SCHEMBL24358023 | 0.85 | KDR (0.43) | MAP3K12SYKIDH2 | |
| SCHEMBL24358123 | 0.84 | SCN9A (0.40) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | TRPV1 1328/4885MAP3K12 2391/4885SCN9A 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.